This glycoengineered monoclonal antibody depletes CCR4-expressing cells by antibody-dependent cell-mediated cytotoxicity (ADCC), and has significant clinical activity in CCR4+ T-cell NHL [115–117]. The gene discussed is CCR4; the disease is T-cell non-Hodgkin lymphoma.